SCHEMBL26849394

SCHEMBL26849394

CC(=O)c1[nH]nnc1-c1ccccc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.40
▸ RAB9A P51151 5/20 0.38
▸ ALDH1A1 P00352 5/20 0.38
▸ NPC1 O15118 4/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ MAPT P10636 3/20 0.38
▸ NOTUM Q6P988 1/20 0.37
▸ DCUN1D1 Q96GG9 1/20 0.37
▸ CASP3 P42574 1/20 0.37
▸ SENP8 Q96LD8 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ SENP6 Q9GZR1 1/20 0.37
▸ HPGD P15428 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ PKM P14618 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ APAF1 O14727 1/20 0.36
▸ TDP2 O95551 1/20 0.36
▸ MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23294571 0.87 HAO1 (0.41) GAARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL23294646 0.83 GAA (0.38) GAARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL15947000 0.78 RAB9A (0.45) GAARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL11496547 0.76 GAA (0.44) GAARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL29244334 0.76 GAA (0.44) GAARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL5601860 0.75 GAA (0.47) GAARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL28327759 0.74 GAA (0.46) GAARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL3387254 0.73 GAA (0.49) GAARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL6065104 0.73 GAA (0.44) GAARAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL23221250 0.70 ALDH1A1 (0.45) GAARAB9AALDH1A1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO GAA 28/4885RAB9A 4019/4885ALDH1A1 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback